This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.
CGCPositive Net Change GTBIFNo Net Change CRLBFPositive Net Change
marijuana medical pot-stocks
Trump Orders Marijuana Reclassification: What It Means for the Sector
by Sundeep Ganoria
Trump's executive order to move marijuana to Schedule III could reshape cannabis regulation and taxes, lifting sentiment around cannabis stocks.
CGCPositive Net Change TLRYPositive Net Change
marijuana medical
Cannabis ETF (CNBS) Hits New 52-Week High
by Zacks Equity Research
CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.
CNBSPositive Net Change
etfs marijuana
Cannabis ETF (WEED) Hits a New 52-Week High
by Sanghamitra Saha
Cannabis ETF WEED hits a new 52-week high, up 226% from its low, as rescheduling hopes fuel momentum and signal potential further upside.
WEEDNegative Net Change
etfs marijuana
Cannabis ETFs Soar Double-Digits on Friday: Here's Why
by Sanghamitra Saha
Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.
MJNegative Net Change TLRYPositive Net Change YOLONegative Net Change CNBSPositive Net Change MSOSPositive Net Change WEEDNegative Net Change
etfs marijuana
Cronos Group Plans Strategic Europe Expansion: How to Play the Stock?
by Sundeep Ganoria
CRON's planned CanAdelaar acquisition boosts its push into the Dutch adult-use cannabis market and highlights its strengthening international momentum.
CRONNo Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical
TLRY Stock Loses 38% in a Month: Should You Buy the Dip?
by Sundeep Ganoria
Tilray's slump deepens as a tighter U.S. hemp rule and a reverse split stir uncertainty despite gains in global cannabis sales.
CGCPositive Net Change TLRYPositive Net Change
marijuana medical
Tilray Brands Strengthens Domestic Lead With Strong Q1 Cannabis Growth
by Sridatri Sarkar
TLRY posts a strong quarter as Canadian cannabis revenues grow and market shares climb across key product categories.
CGCPositive Net Change TLRYPositive Net Change CRLBFPositive Net Change
marijuana medical
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
JAZZPositive Net Change TLRYPositive Net Change
biotechs marijuana medical pot-stocks
TLRY vs. CRLBF: Which Cannabis Player Offers Greater Upside?
by Sridatri Sarkar
Tilray Brands' global expansion and strong Canadian momentum spotlight its edge as investors weigh upside against Cresco Labs' slower growth.
TLRYPositive Net Change CRLBFPositive Net Change
marijuana medical